IL315579A - Small bifunctional compounds to target selective degradation of circulating proteins - Google Patents

Small bifunctional compounds to target selective degradation of circulating proteins

Info

Publication number
IL315579A
IL315579A IL315579A IL31557924A IL315579A IL 315579 A IL315579 A IL 315579A IL 315579 A IL315579 A IL 315579A IL 31557924 A IL31557924 A IL 31557924A IL 315579 A IL315579 A IL 315579A
Authority
IL
Israel
Prior art keywords
target
small molecules
selective degradation
circulating proteins
bifunctional small
Prior art date
Application number
IL315579A
Other languages
English (en)
Hebrew (he)
Inventor
David Spiegel
David Caianiello
Mengwen Zhang
Original Assignee
Univ Yale
David Spiegel
David Caianiello
Mengwen Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/695,645 external-priority patent/US12485178B2/en
Application filed by Univ Yale, David Spiegel, David Caianiello, Mengwen Zhang filed Critical Univ Yale
Publication of IL315579A publication Critical patent/IL315579A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315579A 2022-03-15 2023-03-15 Small bifunctional compounds to target selective degradation of circulating proteins IL315579A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/695,645 US12485178B2 (en) 2018-04-09 2022-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins
PCT/US2023/064470 WO2023178202A2 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (1)

Publication Number Publication Date
IL315579A true IL315579A (en) 2024-11-01

Family

ID=88024440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315579A IL315579A (en) 2022-03-15 2023-03-15 Small bifunctional compounds to target selective degradation of circulating proteins

Country Status (8)

Country Link
EP (1) EP4493222A2 (https=)
JP (1) JP2025509730A (https=)
KR (1) KR20240166514A (https=)
CN (1) CN119255822A (https=)
AU (1) AU2023236291A1 (https=)
IL (1) IL315579A (https=)
MX (1) MX2024011338A (https=)
WO (1) WO2023178202A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
WO2019199621A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
AU2019404061A1 (en) * 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
WO2021155317A1 (en) * 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins

Also Published As

Publication number Publication date
WO2023178202A2 (en) 2023-09-21
JP2025509730A (ja) 2025-04-11
EP4493222A2 (en) 2025-01-22
WO2023178202A3 (en) 2023-10-26
AU2023236291A1 (en) 2024-10-03
MX2024011338A (es) 2024-12-06
KR20240166514A (ko) 2024-11-26
CN119255822A (zh) 2025-01-03

Similar Documents

Publication Publication Date Title
EP3773727A4 (en) BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
IL315579A (en) Small bifunctional compounds to target selective degradation of circulating proteins
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
EP4320126A4 (en) Bifunctional molecules for the selective modification of target substrates
EP3773729A4 (en) Bi-functional molecules to degrade circulating proteins
CL2022001769A1 (es) Anticuerpos anti-cd73 y usos de estos.
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EP3749347A4 (en) COMBINATION THERAPY OF CANCER WITH MULTISPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CL2019002367A1 (es) Composiciones y métodos para la transducción de tumores.
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CL2018000621A1 (es) Ciano tienotriazolpirazinas y usos de las mismas solicitudes relacionadas.
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
EA201991060A1 (ru) Иммунные клетки c модифицированным метаболизмом и их применение
BR112016001978A2 (pt) derivados de ciclopentano 1,3-dissubstituído
WO2016164743A3 (en) Cd38 ligand-drug conjugates for targeted cancer therapy
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
EP3890876A4 (en) LATERAL LOAD OF MICROCAPILLARY ARRANGEMENTS
CA3289724A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
GB2605046B (en) Bolted beam to column connections
DK3277687T3 (da) 7-(Morpholin-4-yl)pyrazol[1,5-a]pyrimidinderivater, som kan anvendes til behandling af immunsygdomme eller inflammatoriske sygdomme eller cancer
IL288144A (en) Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
CL2021001689A1 (es) Ácido r-piridiloxicarboxílico y sal, derivado del éster, método de preparación, composición herbicida y aplicación del mismo.